All In Biotech

Drug Trial Radar · NCT05970172

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

98

Actual

Start

Jan 16, 2024

Primary completion

Oct 30, 2027

Study completion Oct 30, 2027

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood cells. Current treatment for anemia is to have injections of medicines called erythropoietin stimulating agents (also known as ESAs) to help the bone marrow make more red blood cells. These are often given together with iron. This treatment is also available to children and teenagers with CKD. However, there are some safety concerns with ESAs. Also, as roxadustat is taken orally, this may be another option for treating anemia in children and teenagers with CKD. In this study, children and teenagers with CKD and anemia will take roxadustat for up to 52 weeks to treat their anemia. The main aim of the study is to learn how roxadustat affects anemia in children and teenagers with CKD. This is an open-label study which means the children and teenagers in the study and the clinic staff know they will be taking roxadustat. In this study, the children and teenagers with CKD who need treatment for anemia can take part. Those currently being treated with an ESA will be switched to roxadustat. Those who have not been treated with an ESA can start on roxadustat straight away. All children and teenagers in the study will take roxadustat 3 times a week for up to 52 weeks (1 year). They will start on a fixed dose of roxadustat for 4 weeks. Blood samples will be taken regularly to check hemoglobin levels. The roxadustat dose may be changed if the blood levels of hemoglobin are too high, too low, or change too quickly. After 4 weeks the dose may be changed, if needed, to keep blood levels of hemoglobin in the blood to just below the normal range. Firstly, teenagers will take roxadustat. 10 teenagers will take their fixed dose of roxadustat for 4 weeks. They will give blood samples to help the researchers work out the most suitable dose for the rest of the teenagers in the study. When the rest of the teenagers start taking roxadustat at the most suitable dose for teenagers, 10 children will take roxadustat for 4 weeks. These 10 children will give blood samples to help the researchers work out the most suitable dose for the rest of the children in the study. Then, the rest of the children will take roxadustat at the most suitable dose for children. There will be many clinic visits during the study. Overnight hospital stays are not expected. There will be 1 visit every 2 weeks for the first 4 weeks of taking roxadustat, then every 4 weeks until the end of treatment. Finally there is 1 visit 4 weeks after treatment has finished. During most visits, the children and teenagers will have their vital signs checked (blood pressure, body temperature and heart rate). Fluid status (how much water is in the body) will also be checked for those who need dialysis. The children and teenagers will also have blood tests and the study doctors will check for any medical problems. The children and teenagers will have a medical examination before their first dose of roxadustat and again at about 24-week (6-month) and 52-week (13-month) visits. They will have an electrocardiogram (ECG) before their first dose of roxadustat and again at the 12-week, 24-week, 36-week, and 52-week visit. They will also have urine tests at the 4-week, 24-week and 52-week visits. At the 52-week visit, the children and teenagers will also have blood tests for hemoglobin and iron levels. The study doctors will also check for any medical problems.

Conditions

  • Chronic Kidney Disease
  • Renal Anemia

Interventions

  • RoxadustatDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Hb level to the average Hb level over treatment weeks 20 to 24Time frame: Baseline and weeks 20 to 24

Locations

47 sites in 19 countries. Site status is shown where the registry gives one.

  • Site BE32002

    Brussels, Belgium

  • Site BE32005

    Brussels, Belgium

  • Site BE32001

    Edegem, Belgium

  • Site BE32004

    Ghent, Belgium

  • Site BE32003

    Leuven, Belgium

  • Site HR38501

    Zagreb, Croatia

  • Site HR38503

    Zagreb, Croatia

  • Site DK45001

    Aarhus, Denmark

  • Site FI35801

    Helsinki, Finland

  • Site DE49003

    Bonn, Germany

  • Site DE49001

    Tübingen, Germany

  • Site GR30002

    Athens, Greece

  • Site GR30001

    Thessaloniki, Greece

  • Site IE35301

    Dublin, Ireland

  • Site IT39003

    Milan, Italy

  • Site IT39004

    Padova, Italy

  • Site IT39001

    Torino, Italy

  • Site LB96101

    El Achrafiyé, Lebanon

  • Site LT37001

    Vilnius, Lithuania

  • Site NL31002

    Rotterdam, Netherlands

  • Site NO47001

    Bergen, Norway

  • Site NO47002

    Oslo, Norway

  • Site PL48003

    Krakow, Poland

  • Site PL48002

    Warsaw, Poland

  • Site RO40002

    Clug Napoca, Romania

  • Site RO40001

    Timișoara, Romania

  • Site SK42101

    Bratislava, Slovakia

  • Site ES34003

    Esplugues de Llobregat, Spain

  • Site SE46002

    Mölnlycke, Sweden

  • Site SE46003

    Mölnlycke, Sweden

  • Site TR90001

    Ankara, Turkey (Türkiye)

  • Site TR90007

    Ankara, Turkey (Türkiye)

  • Site TR90010

    Ankara, Turkey (Türkiye)

  • Site TR90003

    Istanbul, Turkey (Türkiye)

  • Site TR90004

    Istanbul, Turkey (Türkiye)

  • Site TR90008

    Istanbul, Turkey (Türkiye)

  • Site TR90009

    Istanbul, Turkey (Türkiye)

  • Site TR90005

    İzmit, Turkey (Türkiye)

  • Site TR90006

    Kayseri, Turkey (Türkiye)

  • Site TR90002

    Manisa, Turkey (Türkiye)

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.